Business UpdateJun 29, 2026, 05:36 PM
PetVivo Updates Business, Expands Distribution & Product Pipeline
AI Summary
PetVivo Holdings, Inc. provided a comprehensive business update in its annual report, highlighting its focus on commercializing Spryng®, a lead product for treating osteoarthritis in animals. The company detailed its robust intellectual property portfolio and ongoing clinical studies to support market expansion. PetVivo also announced strategic shifts in its distribution network, terminating previous agreements with MWI and Covetrus, and establishing new partnerships with Vedco Inc. and Clipper Distributing, LLC. Additionally, the company entered an exclusive licensing agreement with VetStem, Inc. for their PrecisePRP product, further expanding its offerings.
Key Highlights
- PetVivo commercializes Spryng®, an intraarticular injection for osteoarthritis in dogs and horses.
- The company holds 10 issued patents (6 US, 4 foreign), 2 US patent applications, and 6 trade secrets.
- Spryng® costs $600-$900 per joint and typically lasts for at least 12 months.
- Terminated non-exclusive distribution agreements with MWI (March 2025) and Covetrus (February 2025).
- Entered new wholesale distribution partnerships with Vedco Inc. and Clipper Distributing, LLC in December 2024.
- Signed an exclusive licensing agreement with VetStem, Inc. for PrecisePRP in February 2025.
- Completed a university clinical study in March 2024 and has ongoing canine clinical studies.
- Operates one ISO 7 certified clean room manufacturing facility, with a second expected to be operational.
Price Impact
More from PETV